Fate therapeutics inc (FATE)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Operating activities
Net loss

-98,149

-66,598

-42,952

-33,462

-29,992

-25,883

-20,894

-14,239

-13,427

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

2,193

1,204

971

881

687

496

571

590

672

Stock-based compensation

17,410

6,293

3,606

3,184

2,400

2,434

1,554

155

172

Issuances of common stock for technology

-

-

-

-

-

-

13

21

-

Amortization of debt discounts and debt issuance costs

115

76

81

139

176

24

394

84

23

Accretion and amortization of premiums and discounts on investments, net

478

335

25

-171

-

-

-

-

-

Amortization of collaboration contract asset

620

42

-

-

-

-

-

-

-

Noncash interest expense

-

373

321

492

651

167

147

121

13

Deferred rent

-

-192

-1,085

7

24

52

195

197

-228

Deferred revenue

-8,526

12,259

-2,105

-2,401

-7,335

-

63

83

646

Issuance on common stock for license agreement

-

6,100

-

-

-

-

-

-

-

Non-cash loss on extinguishment of debt

-

-

30

-

-

-

-

-

-

Cash payments included in loss on extinguishment of debt

-

-

88

-

-

-

-

-

-

Stockbased milestone charges and change in fair value of exchangeable shares

-

-

-

-

-

375

2,767

-

-

Change in fair value of preferred stock warrants

-

-

-

-

-

-

8

-37

-5

Loss on disposal of assets

-

-

-

-

-

-

-18

-

-117

Stock-based milestone charges

-

-

-

-

-

-

-

-12

356

Loss on extinguishment of debt

-

-

-

-

-

3

-

-323

-9

Changes in operating assets and liabilities:
Accounts receivable

-500

500

-

-

-

-

-

-

-

Prepaid expenses and other assets

1,911

2,010

428

381

107

146

1,271

405

-209

Accounts payable and accrued expenses

4,277

4,254

2,511

1,561

477

163

1,578

405

134

Right-of-use assets and lease liabilities, net

774

-

-

-

-

-

-

-

-

Net cash used in operating activities

-83,175

-38,650

-36,817

-29,823

-18,397

-22,419

-15,373

-13,274

-12,145

Investing activities
Proceeds from sale of property and equipment

-

-

-

18

-

-

6

-

202

Purchases of property and equipment

7,395

2,303

1,725

457

1,498

882

244

709

2

Purchases of investments

248,858

55,660

39,971

19,675

-

-

-

-

-

Maturities of investments

98,800

57,500

31,500

16,000

-

-

-

-

-

Net cash provided by investing activities

-157,453

-463

-10,196

-4,114

-1,498

-882

-238

-709

200

Financing activities
Issuance of common stock from equity incentive plans, net of issuance costs

2,522

2,693

205

186

420

142

23

-

-

Repurchase of common stock for cash

-

-

-

-

-

-

-

-

7

Issuance of convertible promissory notes

-

-

-

-

-

-

23,736

-

1,000

Proceeds from public offering of common stock, net of issuance costs

162,406

134,577

43,206

-

4,580

-

-

207

14

Proceeds from public offerings of common stock, net of issuance costs

-

-

-

-

32,149

-

40,480

-

-

Proceeds from CIRM award

-

3,510

-

-

-

-

-

-

-

Proceeds from long–term debt

-

-

15,000

-

-

20,000

-

-

3,400

Payment on convertible promissory note

-

-

-

-

-

-

1,679

-

-

Payments of debt issuance costs

-

-

10

-

-

26

-

-

-

Payments included in loss on extinguishment of debt

-

-

88

-

-

-

-

-

-

Principal repayments of long–term debt

15,000

-

10,764

7,689

1,546

1,750

2,000

250

800

Issuance of preferred stock for cash, net of offering costs

-

-

-

-

-

-

-

16,726

3,500

Net cash provided by financing activities

149,928

140,780

47,356

57,737

35,603

18,366

60,560

16,683

7,107

Net change in cash, cash equivalents and restricted cash

-90,700

101,667

343

23,800

15,708

-4,935

44,949

2,700

-4,838

Supplemental disclosure of cash flow information
Interest paid

2,291

1,242

2,314

1,067

1,353

494

250

282

90

Supplemental schedule of noncash investing and financing activities
Issuance of warrants for common stock in connection with long–term debt

-

-

217

-

-

375

-

-

172

Purchases of property and equipment in accounts payable

602

37

48

-

-

-

-

-

-

Beneficial conversion feature related to convertible notes

-

-

-

-

-

-

336

-

-

Conversion of convertible preferred stock into common stock

-

-

-

-

-

-

56,526

11,889

-

Conversion of convertible notes into common stock

-

-

-

-

-

-

22,076

-

-

Exchange of exchangeable shares into common stock

-

-

-

-

-

-

3,318

-

-

Warrant liability reclassification to equity

-

-

-

-

-

-

192

-

-

Common Stock
Proceeds from private placement issuances of stock, net of issuance costs

-

-

-65

28,849

-

-

-

-

-

Preferred Stock
Proceeds from private placement issuances of stock, net of issuance costs

-

-

-128

36,391

-

-

-

-

-